​

Inhibikase Therapeutics (IKT) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Inhibikase Therapeutics Revenue Highlights

Latest Revenue (Y)

$260.50K

0

Inhibikase Therapeutics Revenue by Period

Inhibikase Therapeutics Revenue by Year

DateRevenueChange
2023-12-31$260.50K111.03%
2022-12-31$123.44K-96.02%
2021-12-31$3.10M343.92%
2020-12-31$698.47K-37.79%
2019-12-31$1.12M-72.22%
2018-12-31$4.04M-

Inhibikase Therapeutics generated $260.50K in revenue during NA 2023, up 111.03% compared to the previous quarter, and up 6.45% compared to the same period a year ago.

Inhibikase Therapeutics Revenue by Quarter

DateRevenueChange
2024-06-30-100.00%
2024-03-31--100.00%
2023-12-31$1.00-100.00%
2023-09-30$79.57K-31.65%
2023-06-30$116.41K80.42%
2023-03-31$64.52K-47.73%
2022-12-31$123.44K1593.05%
2022-09-30$7.29K11.28%
2022-06-30$6.55K-85.77%
2022-03-31$46.03K2267.85%
2021-12-31$1.94K-99.41%
2021-09-30$328.46K-75.90%
2021-06-30$1.36M-3.14%
2021-03-31$1.41M101.46%
2020-12-31$698.47K1753.68%
2020-09-30$37.68K-82.84%
2020-06-30$219.59K-18.91%
2020-03-31$270.79K12.70%
2019-12-31$240.28K93.10%
2019-09-30$124.43K-25.46%
2019-06-30$166.93K-71.76%
2019-03-31$591.10K-14.48%
2018-03-31$691.20K179.41%
2017-03-31$247.38K-

Inhibikase Therapeutics generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

Inhibikase Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
MCRBSeres Therapeutics$126.33M-
SCPHscPharmaceuticals$13.59M$8.05M
NTRBNutriband$2.09M$645.80K
MISTMilestone Pharmaceuticals$1.00M-
LGVNLongeveron$709.00K$468.00K
IKTInhibikase Therapeutics$260.50K-
VRAXVirax Biolabs Group$8.56K$76.50K
ANEBAnebulo Pharmaceuticals--
ANTXAN2 Therapeutics--
DMACDiaMedica Therapeutics--
RNXTRenovoRx--
TPSTTempest Therapeutics--
PMVPPMV Pharmaceuticals--
ONCYOncolytics Biotech--
QNRXQuoin Pharmaceuticals--

IKT Revenue FAQ

What is Inhibikase Therapeutics’s yearly revenue?

Inhibikase Therapeutics's yearly revenue for 2023 was $260.5K, representing an increase of 111.03% compared to 2022. The company's yearly revenue for 2022 was $123.44K, representing a decrease of -96.02% compared to 2021. IKT's yearly revenue for 2021 was $3.1M, representing an increase of 343.92% compared to 2020.

What is Inhibikase Therapeutics’s quarterly revenue?

Inhibikase Therapeutics's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a -100.00% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a -100.00% decrease year-over-year (Q1 2023). IKT's quarterly revenue for Q4 2023 was $1, a -100.00% decrease from the previous quarter (Q3 2023), and a -100.00% decrease year-over-year (Q4 2022).

What is Inhibikase Therapeutics’s revenue growth rate?

Inhibikase Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -91.60%, and for the last 5 years (2019-2023) was -76.80%.